1. Home
  2. STTK vs NPCE Comparison

STTK vs NPCE Comparison

Compare STTK & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.95

Market Cap

459.4M

Sector

Health Care

ML Signal

HOLD

Logo Neuropace Inc.

NPCE

Neuropace Inc.

HOLD

Current Price

$14.27

Market Cap

432.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
NPCE
Founded
2016
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
459.4M
432.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
STTK
NPCE
Price
$6.95
$14.27
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$7.60
$18.33
AVG Volume (30 Days)
502.9K
185.7K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
29.03
EPS
N/A
N/A
Revenue
$1,000,000.00
$99,986,000.00
Revenue This Year
N/A
$0.90
Revenue Next Year
N/A
$24.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.13
52 Week Low
$0.71
$7.56
52 Week High
$7.68
$18.97

Technical Indicators

Market Signals
Indicator
STTK
NPCE
Relative Strength Index (RSI) 65.29 51.64
Support Level $5.75 $14.02
Resistance Level N/A $14.72
Average True Range (ATR) 0.47 0.65
MACD 0.03 0.17
Stochastic Oscillator 61.66 64.16

Price Performance

Historical Comparison
STTK
NPCE

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About NPCE Neuropace Inc.

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Share on Social Networks: